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Abstract
The purine analogues tenofovir and abacavir are precursors of potential substrates for the
enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase). Here, we investigated the
association of ITPase activity and ITPA genotype with the occurrence of adverse events
(AEs) during combination antiretroviral therapy (cART) for human immunodeficiency virus
(HIV) infection. In 393 adult HIV-seropositive patients, AEs were defined as events that led
to stop of cART regimen. ITPase activity4 mmol IMP/mmol Hb/hour was considered as
normal. ITPA genotype was determined by testing two ITPA polymorphisms: c.94C>A (p.
Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). Logistic regression analysis deter-
mined odds ratios for developing AEs. In tenofovir-containing regimens decreased ITPase
activity was associated with less AEs (p = 0.01) and longer regimen duration (p = 0.001). In
contrast, in abacavir-containing regimens decreased ITPase activity was associated with
more AEs (crude p = 0.02) and increased switching of medication due to AEs (p = 0.03).
ITPA genotype wt/wt was significantly associated with an increase in the occurrence of AEs
in tenofovir-containing regimens. Decreased ITPase activity seems to be protective against
occurrence of AEs in tenofovir-containing cART, while it is associated with an increase in
AEs in abacavir-containing regimens.
Introduction
Combination anti-retroviral therapy (cART) for patients infected with the human immunode-
ficiency virus (HIV) has been increasingly effective over the last years. However, adverse events
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(AEs) are still common and can be severe. Predicting whether AEs will occur with specific
antiretroviral drugs would be a valuable tool in the choice of cART regimens. Although deter-
mination of HLA-B57:01 status to predict hypersensitivity for abacavir, is widely used [1], no
other biomarkers or genetic susceptibility traits are known that can be used to predict AEs
associated with cART.
The enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase) is an enzyme which
converts Inosine 5’-triphosphate (ITP) to Inosine 5’-monophosphate (IMP) and Xanthosine
5’-triphosphate (XTP) to Xanthosine 5’-monophosphate (XMP). IMP and XMP are central
metabolites in the purine metabolism, from which Adenosine 5’-monophosphate (AMP) and
Guanosine 5’-monophosphate (GMP) and subsequently Adenosine 5’-triphosphate (ATP)
and Guanosine 5’-triphosphate (GTP) can be formed. ITPase is encoded by the ITPA gene
located on chromosome 20p. ITPA is a polymorphic gene and a substantial part of the Western
population carries one of the single nucleotide polymorphisms (SNPs) ITPA c.94C>A or
ITPA c.124+21A>C [2]. The frequency of c.94C>A is highest in Asian populations (14–10%)
compared to Central/South American (1–2%) and Caucasian and African populations (6–7%)
[2]. The SNP c.124+21A>C is extremely rare in Asian populations [3–5]. These polymor-
phisms result in a decreased ITPase activity [6, 7]. Homozygosity for ITPA c.94 C>A leads to a
null activity solely in erythrocytes, while activity in nucleated cells remains detectable [8]. True
ITPase deficiency in humans is very rare and causes a severe form of early infantile encepha-
lopathy [9]. Decreased ITPase activity and the frequent ITPA SNPs are associated with a
reduced risk to develop ribavirin-induced haemolytic anaemia in patients on treatment for
hepatitis C [10–12], and with an increased risk of AEs in patients treated with thiopurines [13–
15].
Our interest in the role of ITPase in the treatment of HIV-infected patients stems from the
fact that both abacavir and tenofovir as well as didanosine are purine analogues and are there-
fore potential precursors of substrates for ITPase. Similarly to its association with AEs during
the use of thiopurines and ribavirin, ITPase activity might influence the occurrence of AEs
during purine analogues containing cART. Moreover, the majority of HIV-infected patients
showed a decreased erythrocyte ITPase activity compared to healthy controls [16]. Therefore,
we determined whether ITPase activity and ITPA genotype are associated with the occurrence
of AEs during cART with purine analogues in a cohort of HIV-infected patients. In addition,
we tested whether the active metabolites of abacavir and tenofovir (i.e. carbovir-triphosphate
and tenofovir-diphosphate resp.) are substrates for the enzyme ITPase.
Materials and methods
Patients
Consecutive HIV-infected patients attending the outpatient clinic of the Maastricht University
Medical Center in Maastricht, The Netherlands, between March first 2009 and January first
2014, who were treated with cART were included in this study after providing a written
informed consent. Demographic, laboratory and clinical data from the moment the patients
entered medical care for the HIV-infection until January first 2014 were retrieved from the
database of the Dutch HIV monitoring foundation (Stichting HIV Monitoring; SHM), also
known as the AIDS Therapy Evaluation in the Netherlands (ATHENA) and if needed from
the medical records. The SHM includes data on demographics, comorbidities, cART, clinical,
immunological and virological parameters of individuals in HIV care since January 1996 in
any of the 26 HIV treatment centers in the Netherlands. Patients can opt-out after being
informed by their treating physician of the purpose of collection of clinical data. The study was
censored at January first 2014.
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The study was performed according to the Helsinki Declaration and approved by the Medi-
cal Ethical Committee of the Maastricht University Medical Center, Maastricht, The
Netherlands.
ITPase activity
Erythrocyte ITPase activity was determined once per patient in the period of March first 2009
until January first 2014 and determined as described previously [17] and assessed by formation
of inosine monophosphate (IMP) from inosine triphosphate (ITP). ITPase activity was ex-
pressed as mmoles of IMP formed from ITP in one hour per mmol hemoglobin (mmol IMP/
mmol Hb/hour). The cut-off value discriminating between normal or decreased ITPase activ-
ity was set at 4 mmol IMP/mmol Hb/hour, which is the lowest value within the 95% CI for
ITPA wt/wt carriers [16, 18].
In order to test whether or not carbovir-triphosphate and tenofovir-diphosphate are sub-
strates for ITPase, the enzyme activity assay was carried out as described, using 1 millimolar of
ITP, carbovir-triphosphate or tenofovir-diphosphate. Erythrocytes of a non-HIV infected con-
firmed wild type ITPA genotype carrier individual was used for this experiment. Experiments
were performed in triplicate.
Carbovir-triphosphate and tenofovir-diphosphate were obtained from Toronto Research
Chemicals (Toronto, Ontario, Canada).
ITPA genotype analysis
Genomic DNA was isolated from whole blood using the Wizard Genomic DNA purification
kit (Promega, Madison, WI) and genotyped using sanger sequencing for the two ITPA poly-
morphisms; c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101), as previously
described [16]. When both polymorphisms were not detected, the genotype was considered to
be wild type (wt/wt). All sequences were evaluated by two independent laboratory experts.
Adverse events
For a uniform definition of AEs, AEs resulting in stopping or switching of the cART regimen
and AEs that could be objectified in the laboratory were included. AEs were defined as stop-
ping or switching for any reason except for the reasons virological failure, interaction with
other medication, simplification or intensification of the regimen, drug taken off the market,
patient deceased, low cART blood levels. Before statistical analyses, AEs were categorised and
their potential association with ITPase activity or ITPA genotype was determined. The categor-
isation of the AEs was as follows: any AE (all categories of AE named hereafter taken together),
gastro-intestinal (abdominal pain, nausea, diarrhoea, stomach ache, loss of appetite, pancreati-
tis), neurological (psychiatric complaints or dizziness, sleeping disorder, headache, tremor,
disorders of taste), renal (renal insufficiency, kidney stones, nephritis, hypophosphatemia or
lactate acidosis as reported reason for stopping the cART regimen or MDRD <60 ml/min/
1.73 m2 or phosphate <0.6 mmol/L in at least two separate measurements without other obvi-
ous cause), skin (rash or abscess at the site of injection) and liver related (liver failure as
reported reason for stopping the cART regimen or alanine aminotransferase and/or aspartate
aminotransferase >90 U/L without other obvious cause, in at least two separate measure-
ments, or in one measurement in case of only two measurements performed during that
regimen).
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Statistical analysis
Results were analysed using IBM SPSS Statistics 21 (IBM Corporation, New York, USA) and
SAS system for windows version 9.3. Pearson-chi-square-tests, Fisher’s exact test and indepen-
dent samples T-tests were used to determine significant differences. P values<0.05 were con-
sidered to be statistically significant. The occurrence of adverse events was analyzed with
logistic regression with repeated statement and adjusted for cumulative total duration of cART
therapy, cumulative duration of purine analogue therapy of all prior regimens and duration of
the current regimen. Analysis included check for significant interaction with treatment and
ITPase activity. When abacavir, tenofovir or didanosine were used concomitantly in one
cART regimen, these regimens were excluded from the analysis.
Results
Patient characteristics
Of 393 HIV infected patients, 205 (52.2%) patients had a decreased ITPase activity (Table 1).
There were no statistically significant differences with respect to age, gender, ethnicity and
alcohol use between the groups having normal and decreased ITPase activity. Mean CD4 nadir
did not differ significantly between the group of patients with decreased ITPase activity
(216 ± 161 cells/μL) and normal ITPase activity (200 ± 146 cells/μL).
Table 1. Demographic and clinical characteristics of the patients (n = 393) with ITPase activity<4 and4 mmol IMP/mmol Hb/hour.
Characteristic ITPase activity <4a (n = 205) ITPase activity4a (n = 188) P-value
Age; median (min-max) (years) 50.6 (20–81) 49.7 (27–84) 0.80
Male Gender (n / %) 164 (80.0) 155 (82.4) 0.53
Race (n / %) 0.81
White non-Hispanic 164 (80.0) 147 (78.2)
White Hispanic 5 (2.4) 4 (2.1)
Black 22 (10.7) 27 (14.4)
Asian or other 14 (6.9) 10 (5.3)
ITPase activity (mean±S.D.) 2.44 (1.12) 5.24 (1.09) <0.001
ITPA genotype (n / %) <0.001
Wt/wt 90 (43.9) 175 (93.1)
Wt/c.124+21A>C 59 (28.8) 9 (4.8)
Wt/c.94C>A or otherb 53 (25.9) -
Unknown 3 (1.5) 4 (2.1)
Alcohol (IU/day) 0.51
<2 157 (76.6) 133 (70.7)
2 35 (17.1) 36 (19.1)
Unknown 13 (6.3) 19 (10.1)
Recreational drugsc 0.04
None 120 (58.5) 92 (48.9)
Yes 50 (24.4) 55 (29.3)
Unknown 35 (17.1) 41 (21.8)
Hepatitis B co-infection 0.25
No / cleared 182 (88.8) 167 (88.8)
Yes 10 (4.9) 6 (3.2)
Unknown 13 (6.3) 15 (8.0)
Hepatitis C co-infection 0.52
(Continued)
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cART regimens
In total 393 patients accounted for 1464 prescribed regimens. The median number of regimens
per patient was 3, with a maximum of 18 regimens in one patient (Table 1). In total 38.992 per-
son months of anti-retroviral therapy were observed. 9% of the regimens started before 1998.
Purine analogues (tenofovir, abacavir and didanosine) were frequently prescribed (n = 601,
n = 244 and n = 128 respectively) and the proportion of purine analogue containing regimens
(69.3%) did not differ between the group of patients with normal ITPase activity and the
group of patients with decreased ITPase activity (p = 0.09). 17 regimens (1.1%) contained both
tenofovir and didanosine, 16 regimens (1.1%) contained abacavir and didanosine and 9 regi-
mens (0.6%) contained tenofovir and abacavir. These regimens were excluded from further
analysis, so 1422 regimens were used to assess the association of ITPase activity and ITPA
genotype with AEs.
ITPase activity and ITPA genotype in HIV patients
ITPA genotype was determined in 386 patients. The most prominent ITPA genotype was wt/
wt (265 patients, 67.4%). The occurrence of wt/c.124+21A>C and wt/c.94C>A ITPA genotype
variants was 68 (17.3%) and 35 (8.9%) respectively. Other variants occurred in only 4.6% of
the patients (homozygous c.124+21A>C n = 5, homozygous c.94C>A n = 2 and heterozygous
c.124+21A>C/c.94C>A n = 11). Mean ITPase activity correlated with ITPA genotype, with
the highest ITPase activity in the wt/wt genotype. However, within the ITPA genotype wt/wt,
Table 1. (Continued)
Characteristic ITPase activity <4a (n = 205) ITPase activity4a (n = 188) P-value
No 174 (84.9) 159 (84.6)
Yes 27 (13.2) 22 (11.8)
Unknown 4 (2.0) 7 (3.7)
CD4 nadir (mean±S.D.) 215.6 ± 160.9 200.1 ± 145.7 0.32
Year of start (median / min-max) 2006 (1987–2013)d 2006 (1987–2013)e 0.25
% of patients starting cART before the year 1998 9.7 8.3 0.68
Number of cART regimens per patient (median / min-max) 3 (1–14) 3 (1–18) 0.74
Total number of cART regimens 734 688
Duration of cART regimen in months (median / min-max) 18.0 (0–161)f 15.5 (0–160)g 0.06
Purine containing cART (n / %)
Tenofovir
Abacavir
Didanosine
306 (40.1)
131 (17.2)
51 (6.7)
295 (41.1)
113 (15.8)
77 (10.7)
0.09
Duration purine containing cART in months (mean±S.D.)
Tenofovir
Abacavir
Didanosine
29.2 ± 24.7
34.9 ± 35.6
24.7 ± 27.9
22.5 ± 22.0
41.4 ± 40.8
19.4 ± 22.4
0.001
0.19
0.24
a mmol IMP/mmol Hb/hour
b Other = homozygous c.124+21A>C or homozygous c.94C>A or heterozygous c.124+21A>C/c.94C>A
c heroin, cocaine, amphetamines, 3,4-methylenedioxymethamphetamine (MDMA), cannabis, lysergic acid diethylamide (LSD), ketamine, gamma-hydroxybutyric acid
(GHB) and akylnitrate (‘poppers’)
d Year of start missing in 1 patient
e Year of start missing in 2 patients
f Duration of cART regimen missing in 1 patient
g Duration of cART regimen missing in 3 patients
https://doi.org/10.1371/journal.pone.0191069.t001
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90 (34.0%) patients had decreased ITPase activity and within the ITPA genotype wt/c.124+-
21A>C, 9 (13.2%) of the patients had normal ITPase activity. The other ITPA genotypes were
only associated with a decreased ITPase activity.
Association of ITPase activity with AEs
734 regimens were prescribed in 205 patients with decreased ITPase activity and 688 in 188
patients with normal ITPase activity (N.S., Table 1). In 6.8% of the regimens the reason for
switching or stopping cART regimen was unknown. In total, AEs were present during 714 reg-
imens (50.2%) with 356 AEs in patients with decreased ITPase activity and 358 in patients with
normal ITPase activity (N.S.). The occurrence of AEs and the effect of the ITPase activity are
displayed in Table 2 and Fig 1 respectively.
Tenofovir. Normal ITPase activity was significantly associated with AEs in regimens con-
taining tenofovir (167 vs 137 respectively, Odds ratio (OR) 0.65 for decreased ITPase activity
versus normal activity; 95% CI 0.46–0.92; p = 0.01), see Fig 1. Tenofovir-containing regimens
used with normal ITPase activity were significantly more often switched because of AEs than
for other reasons compared to regimens used with a decreased ITPase activity (91 of 281 vs 70
of 293 respectively (reason for switch unknown in 27 regimens), p = 0.02). Furthermore, mean
regimen duration was statistically significantly longer in patients with a decreased ITPase
activity (29.2 vs 22.5 months; p = 0.001), see Table 1.
Of all the renal AEs that occurred, 48.7% were in the group of regimens containing tenofo-
vir (n = 55) and of these 63.6% occurred in the patients with normal ITPase activity (p = 0.04;
OR 0.51; 95% CI 0.27–0.96 for patients with decreased ITPase activity versus normal activity),
see Fig 2.
Abacavir. In regimens containing abacavir 61.2% of all AEs occurred in the patients with
decreased ITPase activity and 38.8% in the patients with normal ITPase activity (crude
p = 0.02). After correction using logistic regression, OR remained elevated for decreased
ITPase activity versus normal ITPase activity (1.69) but did not reach significance (p = 0.08),
see Fig 1. Significantly more often the cART regimen was switched because of AEs instead of
other reasons when ITPase activity was decreased compared to normal ITPase activity (50 of
124 vs 29 of 108 respectively (reason for switch unknown in 12 regimens), p = 0.03). In general,
more adverse events tended to occur in patients with decreased ITPase activity, e.g. gastroin-
testinal and skin related AEs (Fig 2). Of the cART regimens containing abacavir, 6.1% were
stopped or changed because of skin related AEs and 73.3% of these events occurred in the
patients with decreased ITPase activity, however this difference was not statistically significant.
Didanosine and regimens without tenofovir, abacavir and didanosine. No statistically
significant association was found for AEs occurring with use of didanosine or regimens with-
out tenofovir, abacavir and didanosine and ITPase activity.
Table 2. Occurrence of adverse events in patients grouped by ITPase activity, percentage of adverse events and crude p-values per purine type.
cART regimen ITPase activity <4a ITPase activity4a Crude p-value
Adverse events (n) / Patients (n) % of total AE Adverse events (n) / Patients (n) % of total AE
Tenofovir 137/306 45.1% 167/295 54.9% 0.004
Abacavir 74/131 61.2% 47/113 38.8% 0.02
Didanosine 27/51 40.3% 40/77 59.7% 0.91
No purine 118/246 53.2% 104/203 46.8% 0.49
a mmol IMP/mmol Hb/hour
https://doi.org/10.1371/journal.pone.0191069.t002
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Association of ITPA genotype with AEs
The occurrence of AEs and the effect of the ITPA genotype are displayed in Table 3 and Fig 3
respectively. 960 regimens were prescribed for patients with wt/wt genotype and 435 for
patients with one or more of the SNPs. Genotype was unknown for 27 regimens.
Tenofovir. ITPA genotypes other than wt/wt, associated with decreased ITPase activity,
seemed to be protective against AEs (p = 0.04), as 72.4% of all AEs occurred in the patients
Fig 1. Effect ITPase activity on total adverse events. The effect of decreased versus normal ITPase activity on the occurrence of
total adverse events (grouped by regimens containing tenofovir, abacavir or didanosine and regimens without tenofovir, abacavir or
didanosine) is plotted. Odds ratio with 95% confidential interval and matching p-values are displayed. The analyses were conducted
with repeated statement, adjusted for cumulative total duration of cART, cumulative duration of purine analogue therapy of all
prior regimens and duration of the current regimen.
https://doi.org/10.1371/journal.pone.0191069.g001
Fig 2. Effect ITPase activity on regimen associated adverse events. The effect of decreased ITPase activity on the occurrence of regimen
associated adverse events (renal adverse events for tenofovir and gastro-intestinal and skin related adverse events for abacavir) is plotted. Odds
ratio with 95% confidential interval and matching p-values are displayed. The analyses were conducted with repeated statement, adjusted for
cumulative total duration of cART, cumulative duration of purine analogue therapy of all prior regimens and duration of the current regimen.
https://doi.org/10.1371/journal.pone.0191069.g002
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with ITPA genotype wt/wt and 26.3% in patients with SNPs in the genotype. 1.3% Of the regi-
mens with an AE had an unknown genotype. 76.4% of all renal AEs occurred in the regimens
with wt/wt genotype, this difference was not statistically significant, see Fig 4.
Abacavir. No association was found between ITPA genotype and all AEs in patients using
abacavir. For gastro-intestinal AEs a SNP in the ITPA genotype was associated with an
increased number of AEs (OR 3.45 for ITPA genotypes with SNPs versus wt/wt genotype; 95%
CI 0.99–11.11; p = 0.05), see Fig 4.
Didanosine and regimens without tenofovir, abacavir and didanosine. No association
was found between ITPA genotype and AEs in patients using didanosine or regimens without
tenofovir, abacavir and didanosine.
Carbovir-triphosphate and tenofovir-diphosphate are no direct substrates
for ITPase
To test the hypothesis that carbovir-triphosphate could be a substrate for ITPase, resulting in
higher carbovir levels when ITPase activity is decreased, and more pronounced adverse effects,
Table 3. Occurrence of adverse events in patients grouped by ITPA genotype, and crude p-values per purine type for each type of adverse event.
cART
regimen
SNP in ITPA genotypea ITPA genotype wt/wt Genotype unknown Crude p-
value
Adverse events (n) / Patients
(n)
% of total
AE
Adverse events (n) / Patients
(n)
% of total
AE
Adverse events (n) / Patients
(n)
% of total
AE
Tenofovir 80/186 26.3% 220/409 72.4% 4/6 1.3% 0.04
Abacavir 38/75 31.4% 82/164 67.8% 1/5 0.8% 0.52
Didanosine 18/31 26.9% 48/96 71.6% 1/1 1.5% 0.54
No purine 64/143 28.8% 151/291 68.0% 7/15 3.2% 0.36
a heterozygous wt/c.124+21A>C or wt/c.94C>A or homozygous c.124+21A>C or homozygous c.94C>A or compound heterozygous c.124+21A>C/c.94C>A
https://doi.org/10.1371/journal.pone.0191069.t003
Fig 3. Effect ITPA genotype on total adverse events. The effect of ITPA genotype wt/wt versus the other ITPA genotypes on the
occurrence of total adverse events (grouped by regimens containing tenofovir, abacavir or didanosine and regimens without
tenofovir, abacavir or didanosine) is plotted. Other ITPA genotypes than wt/wt were wt/c.124+21A>C, wt/c.94C>A, c.124
+21A>C/c.124+21A>C, c.94C>A/c.94C>A or c.124+21a>C/c.94C>C. Odds ratio with 95% confidential interval and matching
p-values are displayed. The analyses were conducted with repeated statement, adjusted for cumulative total duration of cART,
cumulative duration of purine analogue therapy of all prior regimens and duration of the current regimen.
https://doi.org/10.1371/journal.pone.0191069.g003
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carbovir-triphosphate was directly used as a substrate for ITPase. Carbovir-triphosphate was
not a direct substrate for ITPase and neither was tenofovir-diphosphate.
Discussion
Here, we show for the first time that ITPase activity is associated with the occurrence of AEs in
patients using cART containing the purine analogues tenofovir and abacavir. A significant
reduction in all AEs was found in patients with decreased ITPase activity using tenofovir.
Moreover, mean regimen duration was significantly longer indicating a better tolerance of
tenofovir containing cART regimens in patients with decreased ITPase activity. On the other
hand, patients with decreased ITPase activity using abacavir were more at risk for developing
AEs. Mean regimen duration was longer in the patients with normal ITPase activity, indicating
a better tolerance of abacavir in these patients. No clear association between AEs and regimens
without tenofovir, abacavir or didanosine could be demonstrated.
These data suggest that ITPase activity may be used as a pharmacogenetic biomarker in
patients starting cART containing tenofovir or abacavir. Up to now no other biomarkers are
in use, apart from HLA-B57:01 status to predict abacavir hypersensitivity syndrome. As teno-
fovir is used as a part of the regimen in the PrEP studies to prevent HIV transmission, we
expect an increase in the use of tenofovir by indivuduals not infected with HIV, A test to iden-
tify individuals with increased risk of developing long term adverse effects due to tenofovir
would be an extremely welcome asset. The present study suggest ITPase activity is a potential
candidate.In other diseases, results of studies using ITPA polymorphisms to predict AEs varied
with the purine analogue used. The ITPase lowering ITPA polymorphisms were shown to be
protective against ribavirin-induced anaemia in hepatitis C on treatment [19, 20]. In patients
Fig 4. Effect ITPA genotype on regimen associated adverse events. The effect of ITPA genotype wt/wt versus the other ITPA genotypes on the
occurrence of regimen associated adverse events (renal adverse events for tenofovir and gastro-intestinal and skin related adverse events for
abacavir) is plotted. Other ITPA genotypes than wt/wt were wt/c.124+21A>C, wt/c.94C>A, c.124+21A>C/c.124+21A>C, c.94C>A/c.94C>A or
c.124+21a>C/c.94C>C. Odds ratio with 95% confidential interval and matching p-values are displayed. The analyses were conducted with repeated
statement, adjusted for cumulative total duration of cART, cumulative duration of purine analogue therapy of all prior regimens and duration of the
current regimen.
https://doi.org/10.1371/journal.pone.0191069.g004
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with inflammatory bowel disease using azathioprine, however, adverse events occurred more
frequently in patients with ITPase lowering ITPA polymorphisms [7, 21]. In our study a lower
ITPase activity was associated with less cART regimen switches due to AEs in patients using
tenofovir, whereas regimens containing abacavir were more frequently switched. The underly-
ing cause of the observed differences between the purine analogues tenofovir and abacavir is
yet unclear. Both abacavir and tenofovir are potent inhibitors of HIV reverse transcriptase
[22–24]. However, the chemical structure differs greatly between the two analogues (Fig 5).
Whilst tenofovir is an acyclic adenine nucleotide analogue, abacavir is the prodrug of carbovir,
which is formed by removal of the cyclopropylammonia moiety attached to the purine base
and is a guanosine analogue.
We expect that part of the explanation is to be found in the chemistry of these compounds.
In our hands, both carbovir-triphosphate and tenofovir-diphosphate proved to be non-sub-
strates for ITPase, so the mechanism behind our observation that decreased ITPase activity
leads to an increased occurrence of adverse events in abacavir therapy is not easily explained.
As was hypothesized by Coelho et al [25], the use of cART may lead to an increase in IMP and
so to an increase in cytotoxicity by an increased ITP level in patients with decreased ITPase
Fig 5. Chemical structures. Chemical structures of tenofovir, abacavir, adenosine, carbovir, didanosine, inosine and guanosine.
https://doi.org/10.1371/journal.pone.0191069.g005
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activity. Interestingly, we observed cultured skin fibroblasts of patients with encephalopathy
associated with ITPA mutations [9] leading to severely reduced ITPase activity show increased
levels of IMP rather than ITP when compared to controls, so direct toxicity by ITP can only
explain part of the mechanism involved. Bondoc and coworkers [26] demonstrated that intra-
cellular anabolism of carbovir was stimulated by adenine, adenosine, hypoxanthine, inosine
and even dideoxy-Inosine. Their hypothesis is that increased intracellular levels of IMP and
ATP enhanced the anabolism of carbovir by stimulating phosphorylation by 5’-nucleotidase.
In line with this, we might hypothesize that a decreased ITPase activity leads to an increase in
IMP and so to an increase of carbovir anabolism. In addition to its anti-retroviral activity, car-
bovir-triphosphate has been demonstrated to be a competitive inhibitor of soluble guanylate
cyclase influencing platelet activity [27]. Considering that carbovir-triphosphate might be
increased by decreased ITPase activity, the interference of carbovir-triphosphate in the nitric
oxide (NO) signalling pathway may be considerable, leading to adverse events and regimen
change. This hypothesis needs further investigation to clarify the mechanism.
Skin reactions related to abacavir are an immunological phenomenon. In our study, most
of the skin related adverse events occurred in the abacavir-containing regimens used by
patients with decreased ITPase actvitiy, although this difference was not statistically significant.
The role of ITPase in immunologically induced AEs remains to be elucidated.
For tenofovir an explanation for the present results seems to be less straightforward. Teno-
fovir differs from carbovir in two essential aspects: tenofovir is a nucleoside-monophosphate
and a adenosine analogue rather than a guanosine analogue. Tenofovir metabolites appear to
be resistant to deamination [28] making accumulation of the deaminated tenofovir-diphos-
phate metabolite due to decreased ITPase activity unlikely. At this moment we can only specu-
late that ITPase activity influences tenofovir metabolism in a yet unknown fashion. In this
study we were not able to rule out other factors that may have influenced renal events other
than tenofovir use, like hypertension, diabetes mellitus, age and the use of other medication,
like non-steroidal anti-inflammatory drugs.
All previous studies evaluating the effect of ITPA genotype polymorphisms on adverse events
assumed that the reported ITPase activity directly corresponds to a specific ITPA polymorphism
[14, 18]. However, in accordance with our previous work [29] we found that an ITPA variant
such as wt/c.124+21A>C lead to a variety of ITPase activities from as low as 1.53 to as high as
7.70 mmol IMP/mmol Hb/hour. Moreover, in spite of wt/wt genotype, HIV-infected patients
were found to have a decreased ITPase activity compared to control patients [16] and therefore
more often will have an ITPase activity<4 mmol IMP/mmol Hb/hour. In HIV, the association
between ITPA genotype and ITPase activity is less strict as has previously been assumed. This
may be an explanation why ITPA genotype correlated less to AEs compared to ITPase activity,
as we found in this study. Previously we showed that ITPase activity is lower in HIV-infected
patients compared to control populations in erythrocytes [16] as well as in leukocytes [30] inde-
pendent of ITPA genotype, which did not appear to be an effect of nucleoside analogues [16].
Some limitations of this research need to be mentioned. Because cART is, by definition, a
combination of antiretroviral drugs, adverse events during a cART regimen might be attrib-
uted to more than one drug. However, by using repeated statement and adjusting the statistical
analysis for cumulative total duration of cART, cumulative duration of purine analogue ther-
apy of all prior regimens and duration of the current regimen, we were able to measure the
association between ITPase activity and tenofovir and abacavir containing regimens. More
studies will be needed to confirm our findings.
The lack of more significant results analyzing specific adverse events other than gastro-
intestinal, renal and skin related adverse events in this study may be due to the relatively small
numbers of the occurrence of these adverse events. This was probably due to the fact that in our
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definition of adverse event we only used the reasons for stopping a regimen in combination
with retraceable laboratory values. We have chosen this strategy because in the SHM database
reason for switching cART regimen is a mandatory question, whereas reporting AEs is up to
the physician and not a prerequisite item in the database and therefore is a less reliable parame-
ter. Still, in 7% of the regimens, the reason for switching cART was unknown. The number of
regimens with unknown reason for switching were equally distributed between both ITPase
activity groups. We therefore do not expect this to be affecting the results of the study.
Because the data were collected retrospectively, the causality between the use of cART and
the occurrence of AEs cannot be proven in this study. By using only the reasons for stopping
the cART regimen or retraceable laboratory values, we avoided some bias, however, prospec-
tive trials are needed to confirm our data.
In conclusion, ITPase enzyme activity <4 mmol IMP/mmol Hb/hour seems to be protective
against occurrence of adverse events in cART regimens containing tenofovir, while it leads to
an increase in adverse events in cART regimens containing abacavir. These results warrant fur-
ther elucidation of the mechanism involved and need to be confirmed in a prospective trial.
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